These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21721915)

  • 1. Understanding aberrant white matter development in schizophrenia: an avenue for therapy?
    Walterfang M; Velakoulis D; Whitford TJ; Pantelis C
    Expert Rev Neurother; 2011 Jul; 11(7):971-87. PubMed ID: 21721915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia.
    Walterfang M; Wood SJ; Velakoulis D; Pantelis C
    Neurosci Biobehav Rev; 2006; 30(7):918-48. PubMed ID: 16580728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White matter changes in schizophrenia: evidence for myelin-related dysfunction.
    Davis KL; Stewart DG; Friedman JI; Buchsbaum M; Harvey PD; Hof PR; Buxbaum J; Haroutunian V
    Arch Gen Psychiatry; 2003 May; 60(5):443-56. PubMed ID: 12742865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau.
    Lin WL; Zehr C; Lewis J; Hutton M; Yen SH; Dickson DW
    J Neurocytol; 2005 Dec; 34(6):397-410. PubMed ID: 16902761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss.
    Bennett MR
    Prog Neurobiol; 2011 Nov; 95(3):275-300. PubMed ID: 21907759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. White matter and cognitive function in schizophrenia.
    Dwork AJ; Mancevski B; Rosoklija G
    Int J Neuropsychopharmacol; 2007 Aug; 10(4):513-36. PubMed ID: 17313699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new role for oligodendrocytes and myelination in schizophrenia and affective disorders?
    Schmitt A; Simons M; Cantuti-Castelvetri L; Falkai P
    Eur Arch Psychiatry Clin Neurosci; 2019 Jun; 269(4):371-372. PubMed ID: 31076838
    [No Abstract]   [Full Text] [Related]  

  • 8. Decreasing myelin density reflected increasing white matter pathology in Alzheimer's disease--a neuropathological study.
    Sjöbeck M; Haglund M; Englund E
    Int J Geriatr Psychiatry; 2005 Oct; 20(10):919-26. PubMed ID: 16163742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The myelin-pathogenesis puzzle in schizophrenia: a literature review.
    Karoutzou G; Emrich HM; Dietrich DE
    Mol Psychiatry; 2008 Mar; 13(3):245-60. PubMed ID: 17925796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelin, myelin-related disorders, and psychosis.
    Mighdoll MI; Tao R; Kleinman JE; Hyde TM
    Schizophr Res; 2015 Jan; 161(1):85-93. PubMed ID: 25449713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligodendrocyte pathophysiology: a new view of schizophrenia.
    Segal D; Koschnick JR; Slegers LH; Hof PR
    Int J Neuropsychopharmacol; 2007 Aug; 10(4):503-11. PubMed ID: 17291369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia.
    Haroutunian V; Davis KL
    Int J Neuropsychopharmacol; 2007 Aug; 10(4):499-502. PubMed ID: 17583597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Significance of synaptic connectivity reduction for pathogenesis, clinical picture and course of schizophrenia].
    Rabe-Jabłońska J
    Psychiatr Pol; 2003; 37(6):951-64. PubMed ID: 14727368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The leukoencephalopathy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction.
    van der Voorn JP; Kamphorst W; van der Knaap MS; Powers JM
    Acta Neuropathol; 2004 Jun; 107(6):539-45. PubMed ID: 15042387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myelinization of oligodendrocytes in experimental degeneration of the corpus callosum].
    Demêmes D; Marty R
    Z Mikrosk Anat Forsch; 1980; 94(1):169-78. PubMed ID: 7424084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation.
    Bartzokis G
    Neuropsychopharmacology; 2002 Oct; 27(4):672-83. PubMed ID: 12377404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disturbance of oligodendrocyte differentiation in schizophrenia in relation to main hypothesis of the disease].
    Kolomeets NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):108-117. PubMed ID: 28884727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological underpinnings of treatment resistance in schizophrenia: an hypothesis.
    Bartzokis G; Altshuler L
    Psychopharmacol Bull; 2003; 37(4):5-7. PubMed ID: 15272475
    [No Abstract]   [Full Text] [Related]  

  • 19. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins.
    Flynn SW; Lang DJ; Mackay AL; Goghari V; Vavasour IM; Whittall KP; Smith GN; Arango V; Mann JJ; Dwork AJ; Falkai P; Honer WG
    Mol Psychiatry; 2003 Sep; 8(9):811-20. PubMed ID: 12931208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is activity regulation of late myelination a plastic mechanism in the human nervous system?
    Ullén F
    Neuron Glia Biol; 2009 May; 5(1-2):29-34. PubMed ID: 19785923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.